Ceritinib

別名: LDK378 中文名稱：

目錄號(hào)：S7083 Purity: 99.96%

Ceritinib是一種有效的ALK抑制劑，在無細(xì)胞試驗(yàn)中IC50為0.2 nM。Ceritinib (LDK378)還可抑制IGF-1R、InsR、STK22D和FLT3對(duì)應(yīng)的IC50值分別為8 nM、7 nM、23 nM和60 nM。Phase 3。

Ceritinib Chemical Structure

CAS: 1032900-25-6

規(guī)格	價(jià)格	庫存
5mg	1182.86	現(xiàn)貨
50mg	3868.47	現(xiàn)貨
200mg	10720.71	現(xiàn)貨
1g	23900	現(xiàn)貨
更大包裝有超大折扣
400-668-6834 info@selleck.cn

產(chǎn)品質(zhì)控

批次：純度： 99.96%

99.96

Ceritinib相關(guān)產(chǎn)品

相關(guān)產(chǎn)品	TAE684 (NVP-TAE684) GSK1838705A Repotrectinib (TPX-0005) AZD3463 AP26113-analog (ALK-IN-1) Ensartinib dihydrochloride ASP3026	點(diǎn)擊展開
相關(guān)化合物庫	激酶抑制劑庫酪氨酸激酶抑制劑分子庫 PI3K/Akt 抑制劑庫細(xì)胞周期化合物庫血管生成相關(guān)化合物庫	點(diǎn)擊展開

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系	實(shí)驗(yàn)類型	給藥濃度	孵育時(shí)間	活性描述	文獻(xiàn)信息
KARPAS299	Apoptosis assay	60 nM	24 hrs	Induction of apoptosis in human KARPAS299 cells harboring NPM-ALK at 60 nM after 24 hrs by acridine orange/ethidium bromide staining based fluorescence microscopic method	29174809
SU-DHL1	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human SU-DHL1 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 20 to 200 nM after 1 hr by Western blot analysis	29288940
SU-DHL1	Function assay	20 to 200 nM	1 hr	Inhibition of ALK phosphorylation at Y1278 residue in human SU-DHL1 cells at 20 to 200 nM after 1 hr by Western blot analysis	29288940
NCI-H3122	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human NCI-H3122 cells assessed as reduction in ERK phosphorylation at T202//Y204 residues at 20 to 200 nM after 1 hr by Western blot analysis	29288940
NCI-H3122	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human NCI-H3122 cells assessed as reduction in Akt phosphorylation at S473 residue at 20 to 200 nM after 1 hr by Western blot analysis	29288940
SU-DHL1	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human SU-DHL1 cells assessed as reduction in Akt phosphorylation at S473 residue at 20 to 200 nM after 1 hr by Western blot analysis	29288940
SU-DHL1	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human SU-DHL1 cells assessed as reduction in ERK phosphorylation at T202//Y204 residues at 20 to 200 nM after 1 hr by Western blot analysis	29288940
NCI-H3122	Function assay	20 to 200 nM	1 hr	Inhibition of ALK phosphorylation at Y1278 residue in human NCI-H3122 cells at 20 to 200 nM after 1 hr by Western blot analysis	29288940
NCI-H3122	Function assay	20 to 200 nM	1 hr	Inhibition of ALK in human NCI-H3122 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 20 to 200 nM after 1 hr by Western blot analysis	29288940
SU-DHL1	Function assay	30 nM	16 hrs	Inhibition of ALK autophosphorylation at Y1507 residue in human SU-DHL1 cells at 30 nM after 16 hrs by Western blot analysis	29627725
SU-DHL1	Function assay	30 nM	16 hrs	Inhibition of ALK in human SU-DHL1 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 30 nM after 16 hrs by Western blot analysis	29627725
NCI-H3122	Function assay	50 to 250 nM	16 hrs	Induction of ALK degradation in human NCI-H3122 cells assessed as decrease in ALK phosphorylation at Y1604 at 50 to 250 nM after 16 hrs by immunoblot method	29660984
KARPAS299	Function assay	50 to 250 nM	16 hrs	Induction of ALK degradation in human KARPAS299 cells assessed as decrease in ALK phosphorylation at Y1604 at 50 to 250 nM after 16 hrs by immunoblot method	29660984
KARPAS299	Apoptosis assay	50 nM	24 hrs	Induction of apoptosis in human KARPAS299 cells assessed as unclear cell shrinkage at 50 nM after 24 hrs by Hoechst 33258 staining based inverted fluorescence microscopy	30223120
KARPAS299	Apoptosis assay	50 nM	24 hrs	Induction of apoptosis in human KARPAS299 cells assessed as late apoptotic cells at 50 nM after 24 hrs by AO/EB double staining based inverted fluorescence microscopy	30223120
KARPAS299	Apoptosis assay	50 nM	24 hrs	Induction of apoptosis in human KARPAS299 cells assessed as fragmentation at 50 nM after 24 hrs by Hoechst 33258 staining based inverted fluorescence microscopy	30223120
Ba/F3 NA C1156Y	Growth Inhibition Assay		72 h	IC50=0.071 μM	25727400
Ba/F3 NA WT	Growth Inhibition Assay		72 h	IC50=0.020 μM	25727400
C1156F/D1203N 2809	Growth Inhibition Assay		72 h	IC50=254 ± 99 nM	25749034
E1210K 748	Growth Inhibition Assay		72 h	IC50=187 ± 84 nM	25749034
N1178H 169	Growth Inhibition Assay		72 h	IC50=42 ± 6 nM	25749034
F1174I 184	Growth Inhibition Assay		72 h	IC50=13 ± 0.1 nM	25749034
I1171T 445	Growth Inhibition Assay		72 h	IC50=82 ± 12 nM	25749034
I1171N 519	Growth Inhibition Assay		72 h	IC50=187 ± 87 nM	25749034
C1156F 1293	Growth Inhibition Assay		72 h	IC50=217 ± 115 nM	25749034
G1128S 1022	Growth Inhibition Assay		72 h	IC50=102 ± 38 nM	25749034
WT 70	Growth Inhibition Assay		72 h	IC50=21 ± 8 nM	25749034
Parental(+IL3)	Growth Inhibition Assay		72 h	IC50=1586 ± 173 nM	25749034
Ba/F3 NA L1196M	Growth Inhibition Assay		72 h	IC50=0.042 μM	25727400
Ba/F3 NA L1152R	Growth Inhibition Assay		72 h	IC50=0.288 μM	25727400
Ba/F3 NA G1202R	Growth Inhibition Assay		72 h	IC50=0.277 μM	25727400
Ba/F3 NA G1269A	Growth Inhibition Assay		72 h	IC50=0.019 μM	25727400
Ba/F3 NA S1206Y	Growth Inhibition Assay		72 h	IC50=0.037 μM	25727400
Ba/F3 EA WT	Growth Inhibition Assay		72 h	IC50=0.021 μM	25727400
Ba/F3 EA C1156Y	Growth Inhibition Assay		72 h	IC50=0.026 μM	25727400
Ba/F3 EA L1196M	Growth Inhibition Assay		72 h	IC50=0.019 μM	25727400
Ba/F3 EA L1152R	Growth Inhibition Assay		72 h	IC50=0.099 μM	25727400
Ba/F3 EA G1202R	Growth Inhibition Assay		72 h	IC50=0.467 μM	25727400
Ba/F3 EA G1269A	Growth Inhibition Assay		72 h	IC50=0.033 μM	25727400
Ba/F3 EA S1206Y	Growth Inhibition Assay		72 h	IC50=0.038 μM	25727400
BAF3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay, IC50 = 0.0107 μM.	29288940
NCI-H3122	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.015 μM.	26568289
NCI-H2228	Growth inhibition assay		3 days	Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay, IC50 = 0.015 μM.	29627725
SU-DHL1	Growth inhibition assay		3 days	Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay, IC50 = 0.015 μM.	29627725
DFCI114	Antiproliferative assay		72 hrs	Antiproliferative activity against human DFCI114 cells expressing EML4-ALK G1269A mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.018 μM.	26568289
HCC78	Cytotoxicity assay		72 hrs	Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay, IC50 = 0.018 μM.	27474925
KARPAS299	Cytotoxicity assay		2 to 3 days	Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 0.0228 μM.	23742252
NCI-H3122	Function assay		72 hrs	Inhibition of EML4 fused ALK in human NCI-H3122 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay, CC50 = 0.025 μM.	27915169
BAF3	Function assay		2 to 3 days	Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 0.026 μM.	23742252
KARPAS299	Antiproliferative assay		72 hrs	Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay, IC50 = 0.026 μM.	29174809
NCI-H2228	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay, IC50 = 0.026 μM.	30223120
KARPAS299	Cytotoxicity assay		72 hrs	Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay, IC50 = 0.027 μM.	27474925
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.033 μM.	26568289
NCI-H3122	Function assay		72 hrs	Inhibition of EML4-ALK in human NCI-H3122 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay, CC50 = 0.038 μM.	26923695
NCI-H3122	Function assay		72 hrs	Inhibition of EML4-ALK in human NCI-H3122 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay, CC50 = 0.038 μM.	26923695
NCI-H3122	Function assay		72 hrs	Inhibition of EML4 fused ALK in human NCI-H3122 cells assessed as cell growth inhibition after 72 hrs by SRB assay, CC50 = 0.038 μM.	28385505
Ba/F3	Function assay		72 hrs	Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.041 μM.	26568289
Ba/F3	Function assay		72 hrs	Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.041 μM.	26568289
KARPAS299	Antiproliferative assay		72 hrs	Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay, IC50 = 0.041 μM.	30223120
BAF3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay, IC50 = 0.0549 μM.	29288940
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.057 μM.	26568289
HCC78	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay, IC50 = 0.058 μM.	29174809
HCC78	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay, IC50 = 0.058 μM.	30223120
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.064 μM.	26568289
DFCI76	Antiproliferative assay		72 hrs	Antiproliferative activity against human DFCI76 cells expressing EML4-ALK L1152R mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.072 μM.	26568289
BA/F3	Function assay		72 hrs	Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay, CC50 = 0.075 μM.	26923695
BA/F3	Function assay		72 hrs	Inhibition of EML4 fused ALK L1196M mutant (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay, CC50 = 0.075 μM.	27915169
BA/F3	Function assay		72 hrs	Inhibition of EML4 fused ALK (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay, CC50 = 0.075 μM.	27915169
BAF3	Function assay		72 hrs	Inhibition of ALK L1196M mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by WST-1 assay, CC50 = 0.075 μM.	28385505
KARPAS299	Antiproliferative assay		72 hrs	Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay, IC50 = 0.084 μM.	29288940
SMS-KCNR	Antiproliferative assay		72 hrs	Antiproliferative activity against human SMS-KCNR cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.092 μM.	26568289
NCI-H3122	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay, IC50 = 0.096 μM.	29288940
NCI-H2228	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay, IC50 = 0.099 μM.	29174809
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.101 μM.	26568289
NCI-H2228	Cytotoxicity assay		72 hrs	Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.1026 μM.	25644671
LAN5	Antiproliferative assay		72 hrs	Antiproliferative activity against human LAN5 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.122 μM.	26568289
SU-DHL1	Antiproliferative assay		72 hrs	Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay, IC50 = 0.122 μM.	29288940
Kelly	Antiproliferative assay		72 hrs	Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.142 μM.	26568289
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.164 μM.	26568289
SH-SY5Y	Antiproliferative assay		72 hrs	Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.186 μM.	26568289
BAF3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay, IC50 = 0.234 μM.	29288940
SK-N-SH	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.303 μM.	26568289
BAF3	Function assay		2 to 3 days	Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 0.3195 μM.	23742252
SK-N-FI	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.349 μM.	26568289
CHLA20	Antiproliferative assay		72 hrs	Antiproliferative activity against human CHLA20 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.363 μM.	26568289
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.444 μM.	26568289
LAN1	Antiproliferative assay		72 hrs	Antiproliferative activity against human LAN1 cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.549 μM.	26568289
SK-N-BE(2)	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-BE(2) cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 0.593 μM.	26568289
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 0.668 μM.	26568289
BAF3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay, IC50 = 0.726 μM.	29288940
Ba/F3	Function assay		72 hrs	Inhibition of human EGFR del19/T790M/C797S mutant expressed in mouse Ba/F3 cells assessed as cell growth inhibition after 72 hrs by CellTiter-Glo assay, GI50 = 0.7805 μM.	29136465
SK-N-AS	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay, EC50 = 1.045 μM.	26568289
BAF3	Cytotoxicity assay		2 to 3 days	Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay, IC50 = 2.477 μM.	23742252
Ba/F3	Function assay		72 hrs	Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 2.747 μM.	26568289
BA/F3	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay, IC50 = 5.512 μM.	26568289
SH-SY5Y	Antiproliferative assay		72 hrs	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
CHLA20	Antiproliferative assay		72 hrs	Antiproliferative activity against human CHLA20 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
SH-SY5Y	Antiproliferative assay		72 hrs	Antiproliferative activity against human SH-SY5Y cells after 72 hrs in presence of ABCB1 inhibitor tariquidar by CellTiter-Glo luminescent cell viability assay	29660984
CHLA20	Antiproliferative assay		72 hrs	Antiproliferative activity against human CHLA20 cells after 72 hrs in presence of ABCB1 inhibitor tariquidar by CellTiter-Glo luminescent cell viability assay	29660984
NCI-H3122	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
KARPAS299	Antiproliferative assay		72 hrs	Antiproliferative activity against human KARPAS299 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
SU-DHL1	Antiproliferative assay		72 hrs	Antiproliferative activity against human SU-DHL1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	29660984
KARPAS299	Cytotoxicity assay			Cytotoxicity against human KARPAS299 cells expressing NPM-ALK fusion gene assessed as growth inhibition, IC50 = 0.0228 μM.	23837797
BA/F3	Cytotoxicity assay			Cytotoxicity against mouse BA/F3 cells expressing NPM-ALK fusion gene assessed as growth inhibition, IC50 = 0.026 μM.	23837797
NCI-H3122	Antiproliferative assay			Antiproliferative activity against wild type human NCI-H3122 cells, CC50 = 0.038 μM.	26235945
BA/F3	Function assay			Inhibition of ALK (unknown origin) transfected in mouse BA/F3 cells, IC50 = 0.0407 μM.	23837797
BAF3	Antiproliferative assay			Antiproliferative activity against mouse BAF3 cells expressing ALK L1196M mutant, CC50 = 0.075 μM.	26235945
BA/F3	Cytotoxicity assay			Cytotoxicity against mouse BA/F3 cells transfected with Tel-InsR gene assessed as growth inhibition, IC50 = 0.32 μM.	23837797
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述

特性

不與c-Met交叉反應(yīng)，對(duì)體內(nèi)葡萄糖穩(wěn)態(tài)比TAE684效果好，有效作用于 Crizotinib復(fù)發(fā)的腫瘤。

靶點(diǎn)

ALK ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	STK22D ^[1] (Cell-free assay)	FLT3 ^[1] (Cell-free assay)
0.2 nM	7 nM	8 nM	23 nM	60 nM

體外研究(In Vitro)
體外研究活性	LDK378作用于Ba/F3-NPM-ALK和Karpas290細(xì)胞，具有顯著的抗增殖活性，IC50分別為26.0 nM 和 22.8 nM,作用于Ba/F3-Tel-InsR 和Ba/F3-WT細(xì)胞，IC50分別為319.5 nM 和 2477 nM。^[1]
激酶實(shí)驗(yàn)	激酶分析
激酶實(shí)驗(yàn)	所有激酶使用桿狀病毒表達(dá)技術(shù)表達(dá)為組氨酸或GST標(biāo)簽的融合蛋白，除了在大腸桿菌中產(chǎn)生的未標(biāo)記的ERK2。在LabChip遷移實(shí)驗(yàn)中測(cè)量激酶活性。實(shí)驗(yàn)在30°C下進(jìn)行60分鐘。在有或無LDK378存在時(shí)，通過線性進(jìn)展曲線，獲得LDK378對(duì)酶活性的作用效果。
細(xì)胞實(shí)驗(yàn)	細(xì)胞系	Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 細(xì)胞
	濃度	~100 μM
	孵育時(shí)間	2-3 天
	方法	表達(dá)熒光素酶的細(xì)胞與連續(xù)稀釋的LDK378 或 DMSO 溫育2-3天。熒光素酶的表達(dá)用來衡量細(xì)胞增殖/存活，使用Bright-Glo螢光素酶檢測(cè)系統(tǒng)來評(píng)估。使用 XLFit軟件獲得 IC50值。
實(shí)驗(yàn)圖片	檢測(cè)方法	檢測(cè)指標(biāo)	實(shí)驗(yàn)圖片	PMID
	Western blot	p-ALK / ALK / p-AKT / AKT / p-ERK / ERK pROS1 / ROS1 / pSTAT3 / STAT3		28425916
	Growth inhibition assay	Cell viability		29067644

體內(nèi)研究(In Vivo)
體內(nèi)研究活性	LDK378 用于降低形成反應(yīng)代謝的可能性，在肝微粒體幾乎檢測(cè)不到谷胱甘肽（GSH）加合物的水平（<1％）。LDK378具有相對(duì)良好的代謝穩(wěn)定性，中度抑制CYP3A4（Midazolam底物）和抑制hERG。LDK378處理動(dòng)物，與肝臟血流量相比，具有低的血漿清除率（小鼠，大鼠，狗和猴），處理小鼠，大鼠，狗和猴的口服生物利用度都在55％以上。LDK378 處理Karpas299 和H2228 大鼠移植瘤模型，抑制腫瘤生長(zhǎng)，誘導(dǎo)腫瘤衰退，這種作用具有劑量依賴性，體重沒有降低。LDK378處理小鼠，劑量高達(dá)100 mg/kg，對(duì)胰島素水平或血漿葡萄糖的利用無影響。^[1]
動(dòng)物實(shí)驗(yàn)	Animal Models	攜帶 Karpas299/H2228腫瘤的 RNU裸鼠
	Dosages	~50 mg/kg
	Administration	口服飼喂

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試驗(yàn)信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT02450903	Completed	Non-Small-Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	August 21 2015	Phase 2
NCT02040870	Completed	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	March 7 2014	Phase 1\|Phase 2
NCT01950481	Completed	Normal Hepatic Function\|Impaired Hepatic Function	Novartis Pharmaceuticals\|Novartis	January 2014	Phase 1
NCT01772797	Completed	Anaplastic Lymphoma Kinase (ALK)\|Non-small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	June 2013	Phase 1
NCT01685060	Completed	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	November 26 2012	Phase 2
NCT01634763	Completed	Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)	Novartis Pharmaceuticals\|Novartis	June 2012	Phase 1

參考文獻(xiàn)
[1] Marsilje TH, et al. J Med Chem. 2013, Jun 6.

參考文獻(xiàn)

[1] Marsilje TH, et al. J Med Chem. 2013, Jun 6.

化學(xué)信息&溶解度

分子量	558.14	分子式	C₂₈H₃₆ClN₅O₃S
CAS號(hào)	1032900-25-6	SDF	Download Ceritinib SDF
Smiles	CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
儲(chǔ)存條件(自收到貨起)	3年-20°C粉狀	儲(chǔ)備液保存和期限建議分裝儲(chǔ)備液，避免反復(fù)凍融！	1年-80°C溶于溶劑
儲(chǔ)存條件(自收到貨起)	3年-20°C粉狀	儲(chǔ)備液保存和期限建議分裝儲(chǔ)備液，避免反復(fù)凍融！	1個(gè)月-20°C溶于溶劑

體外溶解度
批次：

DMSO : 4 mg/mL ( (7.16 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 20 mg/mL ( (35.83 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO)

Ethanol : 3 mg/mL (5.37 mM)

Water : Insoluble

Ethanol : 5 mg/mL (8.95 mM)

DMSO : 3 mg/mL ( (5.37 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO)

Water : Insoluble

摩爾濃度計(jì)算器

體內(nèi)溶解度
批次：

現(xiàn)配現(xiàn)用，請(qǐng)按從左到右的順序依次添加，澄清后再加入下一溶劑

動(dòng)物體內(nèi)配方計(jì)算器

實(shí)驗(yàn)計(jì)算

摩爾濃度計(jì)算器

質(zhì)量	濃度	體積	分子量
=	×	×

稀釋計(jì)算器分子量計(jì)算器

動(dòng)物體內(nèi)配方計(jì)算器（澄清溶液）

第一步：請(qǐng)輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動(dòng)物的藥量）

給藥劑量 mg/kg 動(dòng)物平均體重 g 每只動(dòng)物給藥體積 μL 動(dòng)物數(shù)量只

第二步：請(qǐng)輸入動(dòng)物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請(qǐng)聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

計(jì)算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請(qǐng)先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH₂O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運(yùn)輸、儲(chǔ)存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會(huì)在24小時(shí)內(nèi)盡快聯(lián)系您。

操作手冊(cè)

如果有其他問題，請(qǐng)給我們留言。

* 必填項(xiàng)

常見問題及建議解決方法

問題 1:
how to reconstitute the inhibitor for oral administration to mice?

回答：
You can resuspend LDK378 in 30% PEG400/0.5% Tween 80/5% propylene glycol and use the suspension for oral gavage feeding.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Ceritinib

產(chǎn)品質(zhì)控

Ceritinib相關(guān)產(chǎn)品

相關(guān)信號(hào)通路圖

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

生物活性

化學(xué)信息&溶解度

實(shí)驗(yàn)計(jì)算

技術(shù)支持

常見問題及建議解決方法